Chrysalin Evidence Guide
Chrysalin (TP508) has Phase 2 human data in bone fracture healing showing accelerated radiographic healing, particularly in osteoporotic patients. The thrombin-receptor mechanism is scientifically distinct from other healing peptides. Phase 2 results are promising but Phase 3 data is not yet available. A credible but not yet fully validated healing compound.
Our Take
Chrysalin (TP508) has Phase 2 human data in bone fracture healing showing accelerated radiographic healing, particularly in osteoporotic patients. The thrombin-receptor mechanism is scientifically distinct from other healing peptides. Phase 2 results are promising but Phase 3 data is not yet available. A credible but not yet fully validated healing compound.
- Best for
- Bone fracture healing acceleration, osteoporotic fracture recovery, thrombin receptor agonism research
- Evidence grade
- Level C
- Confidence
- Moderate
- Starting point
- 10-100mcg local injection at fracture site (Phase 2 dosing ranges)
Benefits and Evidence
- Bone Fracture Healing: Level C, includes human evidence - Phase 2 clinical trials for distal radius fractures demonstrated accelerated radiographic healing and improved functional recovery compared to placebo.
- Soft Tissue Wound Healing: Level D, mostly non-human evidence - Stiernberg et al. (2000, J Surg Res) showed TP508 (Chrysalin) at 1-10 ug/wound accelerated dermal closure by 30% in streptozotocin-diabetic rats with improved granulation tissue density; Carney et al. (2001, Wound Repair Regen) confirmed enhanced angiogenesis in porcine full-thickness wound models.
- Spinal Fusion Enhancement: Level D, mostly non-human evidence - Animal studies demonstrate enhanced spinal fusion rates when TP508 is applied to fusion sites, with improved bone bridging and mechanical strength.
Side Effects and Warnings
- Well-tolerated in Phase 2 trials
- Mild injection site discomfort
- No systemic coagulation effects observed
- No significant adverse events reported in clinical studies
- Not yet FDA-approved; still in clinical development
- Theoretical concern regarding thrombin receptor activation in patients with thrombotic tendencies
- Limited data in patients with impaired healing (diabetes, immunosuppression)
- Long-term safety profile not fully established
Research Dosage References
- <strong>Local injection (fracture site)</strong> - 100-200 mcg - Single dose at time of fracture treatment - Injected directly into the fracture hematoma in clinical trials. Single application was effective in promoting healing.
- <strong>Topical (wound application)</strong> - 1-10 mcg/cm2 - Every 2-3 days - Applied in hydrogel formulation to wound surface in preclinical studies.
Mechanism of Action
Chrysalin promotes tissue repair through thrombin receptor-mediated mechanisms: 1. PAR-1 activation: Binds and activates protease-activated receptor 1 (PAR-1) on endothelial cells, fibroblasts, and osteoblasts, triggering repair signaling cascades. 2. Angiogenesis stimulation: Upregulates VEGF and promotes endothelial cell proliferation, increasing blood vessel formation at fracture and wound sites. 3. Osteoblast stimulation: Directly promotes osteoblast proliferation and differentiation, enhancing callus formation and bone mineralization. 4. Anti-inflammatory effects: Modulates inflammatory cytokine production to optimize the healing environment without excessive inflammation.
Legal Status
Chrysalin (TP508) is an investigational drug that has completed Phase 2 clinical trials. Not yet FDA-approved. Orphan drug designation has been explored for certain indications. Available only through clinical trials or research suppliers.
Primary Sources
- TP508 accelerates fracture healing in a phase II clinical trial for distal radius fractures. J Orthop Trauma, 2004.
- Thrombin peptide TP508 stimulates angiogenesis and wound healing. J Surg Res, 2000.